Royalty Pharma (RPRX) Capital Expenditures (QoQ) (2019 - 2026)
Royalty Pharma (RPRX) Capital Expenditures (QoQ) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Royalty Pharma | 25.78 Bn | 28.22 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -38.34% |
| Dec 31, 2025 | -23.72% |
| Sep 30, 2025 | 86,244.08% |
| Jun 30, 2025 | 5.39% |
| Mar 31, 2025 | -99.79% |
| Dec 31, 2024 | -58.44% |
| Sep 30, 2024 | 63.95% |
| Jun 30, 2024 | 746.42% |
| Mar 31, 2024 | -91.41% |
| Dec 31, 2023 | 122.16% |
| Sep 30, 2023 | 646.34% |
| Jun 30, 2023 | -89.95% |
| Mar 31, 2023 | 140.45% |
| Dec 31, 2022 | -80.99% |
| Sep 30, 2022 | 652.14% |
| Jun 30, 2022 | 205,791.76% |
| Mar 31, 2022 | -99.95% |
| Dec 31, 2021 | -87.15% |
| Sep 30, 2021 | 639.48% |
| Jun 30, 2021 | -64.09% |